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Benzophenone-3 [2-hydroxy-4-methoxy-
benzophenone, oxybenzophenone (BP-3)], a
commonly used sunscreen agent that absorbs
and dissipates ultraviolet radiation, is used in
a variety of cosmetic products (Gonzalez et al.
2006; National Library of Medicine 2007;
Rastogi 2002). BP-3 also has been used as
ultraviolet stabilizer in plastic surface coatings
for food packaging to prevent polymer or
food photodegradation (Suzuki et al. 2005)
and is approved by the U.S. Food and Drug
Administration as an indirect food additive.
Human exposure to BP-3 has not been
associated with adverse health effects, and acute
toxicity from BP-3 is low. However, results
from animal studies—primarily dietary studies
that affected body weight gain—showed alter-
ations in liver, kidney, and reproductive organs
in rats and mice administered BP-3 dermally
and orally (National Toxicology Program
1992). Although the maximum dose that could
be administered dermally was similar to the
lowest orally administered dose, which pro-
duced little systemic toxicity, these results sug-
gested that oral and dermal exposure routes
might affect the animals similarly (National
Toxicology Program 1992). BP-3 also shows
estrogen-like activity in vitro and in vivo
(Schlumpf et al. 2001, 2003, 2004a, 2004b;
Suzuki et al. 2005), although in one study
BP-3’s estrogenic activity was observed only in
the presence of a rat liver preparation, suggest-
ing metabolic activation of BP-3 (Morohoshi
et al. 2005). BP-3 can also display antiandro-
genic activity in vitro (Ma et al. 2003;
Schreurs et al. 2005). Thus, BP-3 might
exhibit endocrine-disrupting action via both
mechanisms in animals. Therefore, in vivo
effects due to these combined activities should
be further investigated.
The focus of pharmaceuticals and ingredi-
ents in personal care products, including
organic sunscreen agents, as environmental
pollutants is increasing because these com-
pounds may enter the aquatic environment
not primarily as a result of manufacturing
practices but from their steady and wide-
spread use in human and veterinary daily
activities. Furthermore, little is known about
the potential hazards associated with recur-
ring human or ecologic exposures to these
synthetic substances, many of which are
bioactive (Daughton 2002; Daughton and
Ternes 1999). BP-3, one of these substances,
has been detected in surface waters (Balmer
et al. 2005; Cuderman and Heath 2007),
drinking water (Loraine and Pettigrove 2006;
Stackelberg et al. 2004), and wastewater
[Balmer et al. 2005; Centers for Disease
Control and Prevention (CDC) 2003;
Loraine and Pettigrove 2006] in North
America and in Europe.
The widespread inclusion of sunscreen
agents in personal care and consumer prod-
ucts (Gonzalez et al. 2006; National Library
of Medicine 2007; Rastogi 2002) increases
the potential for human exposure to BP-3.
Data support the absorption of BP-3 through
human skin (Gonzalez et al. 2006; Hayden
et al. 2005; Janjua et al. 2004; Jiang et al.
1999; Sarveiya et al. 2004). Application of
some of these products to large areas of the
body and frequent reapplication increase the
daily systemic absorption of BP-3. In some
cases, as much as 10% of the applied dose can
be absorbed (Jiang et al. 1999).
Like many xenobiotics, BP-3 undergoes
phase I and phase II biotransformations. In
rats, after oral and dermal administrations of
100 mg BP-3/kg body weight (Kadry et al.
1995; Okereke et al. 1993, 1994, 1995), the
parent compound and three oxidative
metabolites (2,4-dihydroxylbenzophenone,
2,2´-dihydroxy-4-methoxybenzophenone,
and 2,3,4-trihydroxybenzophenone) were
detected in plasma, tissues, and urine. Urine
was the major route of excretion; BP-3 and its
metabolites were excreted mainly as glu-
curonide conjugates (Kadry et al. 1995;
Okereke et al. 1993). Similarly, BP-3 and
2,4-dihydroxylbenzophenone were detected
in human urine collected after a volunteer
applied a commercially available sunscreen
(Felix et al. 1998). These data suggest that the
conjugated species of BP-3 and its metabo-
lites in urine can be used as biomarkers of
exposure. Oxidative metabolites of BP-3 can
themselves be used as sunscreen agents.
Although BP-3 can be biotransformed to sev-
eral metabolites, exposure to BP-3 can be
assessed by measuring the total (free plus con-
jugated) concentrations of BP-3 in urine.
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BACKGROUND: The capability of benzophenone-3 (BP-3) to absorb and dissipate ultraviolet radiation
facilitates its use as a sunscreen agent. BP-3 has other uses in many consumer products (e.g., as
fragrance and ﬂavor enhancer, photoinitiator, ultraviolet curing agent, polymerization inhibitor).
OBJECTIVES: Our goal was to assess exposure to BP-3 in a representative sample of the U.S. general
population ≥ 6 years of age.
METHODS: Using automated solid-phase extraction coupled to high-performance liquid chromatog-
raphy–tandem mass spectrometry, we analyzed 2,517 urine samples collected as part of the
2003–2004 National Health and Nutrition Examination Survey. 
RESULTS: We detected BP-3 in 96.8% of the samples. The geometric mean and 95th percentile
concentrations were 22.9 µg/L (22.2 µg/g creatinine) and 1,040 µg/L (1,070 µg/g creatinine),
respectively. Least-square geometric mean (LSGM) concentrations were significantly higher
(p ≤ 0.04) for females than for males, regardless of age. LSGM concentrations were signiﬁcantly
higher for non-Hispanic whites than for non-Hispanic blacks (p ≤ 0.01), regardless of age. Females
were more likely than males [adjusted odds ratio (OR) = 3.5; 95% conﬁdence interval (95% CI),
1.9–6.5], and non-Hispanic whites were more likely than non-Hispanic blacks (adjusted OR = 6.8;
95% CI, 2.9–16.2) to have concentrations above the 95th percentile.
CONCLUSIONS: Exposure to BP-3 was prevalent in the general U.S. population during 2003–2004.
Differences by sex and race/ethnicity probably reﬂect differences in use of personal care products
containing BP-3.
KEY WORDS: benzophenone-3, biomonitoring, exposure, human, NHANES 2003–2004, sunscreen,
urine. Environ Health Perspect 116:893–897 (2008). doi:10.1289/ehp.11269 available via
http://dx.doi.org/ [Online 21 March 2008]The detection of BP-3 in the aquatic envi-
ronment and the widespread use of products
containing BP-3 have raised interest about
assessing human exposure to this compound
for risk assessment. We report here the first
nationally representative data on the urinary
concentrations of BP-3 in the U.S. general
population ≥ 6 years of age, stratiﬁed by age
group, sex, and race/ethnicity.
Materials and Methods
The National Health and Nutrition
Examination Survey (NHANES), conducted
continuously since 1999 by the CDC, assesses
the health and nutritional status of the civil-
ian noninstitutionalized U.S. population ≥ 2
months of age (CDC 2003). The survey
includes household interviews, medical histo-
ries, standardized physical examinations, and
collection of biologic specimens, some of
which can be used to assess exposure to envi-
ronmental chemicals. NHANES 2003–2004
included examinations of 9,282 people (CDC
2006a). We measured BP-3 by analyzing a
random one-third subset of urine samples (n
= 2,517) collected from NHANES partici-
pants ≥ 6 years of age. Because this subset was
randomly selected from the entire set, it
maintained the representativeness of the sur-
vey. Participants provided informed written
consent; parents provided informed written
consent for their children.
Urine specimens were shipped on dry
ice to the CDC’s National Center for
Environmental Health and stored frozen at or
below –20°C until analyzed. We measured
total (free plus conjugated species) concentra-
tions of BP-3 in urine by online solid-phase
extraction coupled to high-performance liquid
chromatography–tandem mass spectrometry
described in detail elsewhere (Ye et al. 2005a).
Briefly, conjugated BP-3 in 100 µL of urine
was hydrolyzed using β-glucuronidase/
sulfatase (Helix pomatia; Sigma Chemical Co.,
St. Louis, MO). After hydrolysis, samples were
acidified with 0.1 M formic acid; BP-3 was
preconcentrated by online solid-phase extrac-
tion, separated by reversed-phase high-perfor-
mance liquid chromatography, and detected by
atmospheric pressure chemical ionization–
tandem mass spectrometry. Because a stable
isotope-labeled BP-3 was not available, we used
13C12-bisphenol A as internal standard (Ye
et al. 2005a). The limit of detection (LOD),
calculated as 3S0, where S0 is the standard devi-
ation as the concentration approaches zero
(Taylor 1987), was 0.34 µg/L, and the preci-
sion ranged from 17.6% (at 18.5 µg/L) to
16.2% (at 46 µg/L). Low-concentration (~ 20
µg/L) and high-concentration (~ 45 µg/L)
quality control materials, prepared from pooled
human urine, were analyzed with standard,
reagent blank, and NHANES samples (Ye
et al. 2005a).
We analyzed the data using Statistical
Analysis System (version 9.1.3; SAS Institute,
Inc., Cary, NC) and SUDAAN (version 9.0.1;
Research Triangle Institute, Research Triangle
Park, NC). SUDAAN calculates variance esti-
mates after incorporating the sample popula-
tion weights, nonresponse rates, and sample
design effects. We calculated the percentage of
detection and the geometric mean and distrib-
ution percentiles for both the volume-based
(in micrograms per liter urine) and creatinine-
corrected (in micrograms per gram creatinine)
concentrations. For concentrations below the
LOD, as recommended for the analysis of
NHANES data (CDC 2006b), we used a
value equal to the LOD divided by the square
root of 2 (Hornung and Reed 1990).
A composite racial/ethnic variable based
on self-reported data defined three major
racial/ethnic groups: non-Hispanic black,
non-Hispanic white, and Mexican American.
We included participants not deﬁned by these
racial/ethnic groups only in the total popula-
tion estimate. Age, reported in years at the
last birthday, was stratified in groups (6–11,
12–19, 20–59, and ≥ 60 years of age) for cal-
culation of the geometric mean and the vari-
ous percentiles.
We used analysis of covariance to examine
the inﬂuence of several variables, selected on
the basis of statistical, demographic, and bio-
logic considerations, on the concentrations of
BP-3. For the multiple regression models, we
used the variables described below and all
possible two-way interactions to calculate the
adjusted least square geometric mean
(LSGM) concentrations. LSGM concentra-
tions provide geometric mean estimates (in
micrograms per liter) after adjustment for all
covariates in the model. Because the distribu-
tions of BP-3 and creatinine concentrations
were skewed, these variables were log trans-
formed. We analyzed two separate models:
one for adults (≥ 20 years of age) and one for
children and teenagers (≤ 19 years of age).
We considered age (continuous), age squared,
sex, race/ethnicity, and log-transformed crea-
tinine concentration for both models. When
the model included both age and age squared,
we centered age by subtracting 50 from each
participant’s age, thus avoiding multi-
collinearity and obtaining the least weighted
correlation between these two variables
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Table 1. Geometric mean and selected percentiles of BP-3 concentrations in urine for the U.S. population ≥ 6 years of age: data from NHANES 2003–2004.a
Selected percentile
Variableb Geometric mean 10th 25th 50th 75th 90th 95th Sample (n)
Total 22.9 (18.1–28.9) 2.20 (1.50–2.60) 5.80 (4.70–7.10) 18.0 (15.3–23.1) 94.0 (67.5–123) 364 (225–570) 1,040 (698–1,390) 2,517
22.2 (17.6–28.0) 2.28 (1.73–2.89) 5.24 (4.27–6.21) 16.2 (12.7–21.6) 82.0 (58.7–108) 409 (283–577) 1,070 (686–1,600) 2,514
Age group (years)
6–11 21.2 (16.4–27.3) 3.60 (2.40–4.50) 6.70 (5.20–9.50) 17.2 (14.9–25.9) 63.6 (38.7–102) 154 (106–246) 227 (154–618) 314
25.8 (19.5–34.1) 4.30 (2.86–5.19) 8.25 (5.98–10.5) 22.4 (14.4–33.7) 83.6 (41.0–131) 171 (132–365) 427 (171–710) 314
12–19 22.9 (18.0–29.3) 3.30 (2.30–4.10) 7.80 (5.60–9.60) 20.0 (16.1–25.1) 66.5 (45.2–93.8) 170 (137–240) 407 (183–717) 715
17.2 (13.7–21.5) 3.17 (2.24–4.03) 5.86 (4.81–6.93) 12.9 (10.3–16.5) 42.9 (29.5–57.7) 136 (91.7–239) 350 (173–646) 713
≥ 20 23.1 (18.0–29.6) 1.80 (1.20–2.40) 5.50 (4.50–6.70) 18.1 (14.7–23.3) 108 (72.1–140) 450 (315–733) 1,200 (769–1,750) 1,488
22.8 (17.8–29.1) 1.98 (1.48–2.59) 4.89 (3.71–6.12) 16.2 (12.7–21.9) 93.2 (66.0–130) 486 (361–700) 1,330 (880–1,880) 1,487
Sex
Female 30.7 (23.7–39.8) 2.50 (1.80–3.40) 7.30 (5.40–9.10) 26.0 (20.2–34.1) 137 (105–172) 596 (403–769) 1,340 (776–1,790) 1,288
35.5 (27.1–46.4) 3.16 (2.28–4.13) 7.42 (5.83–9.39) 28.2 (20.2–37.0) 144 (101–224) 686 (491–1,130) 1,850 (1,220–2,580) 1,286
Male 16.8 (13.2–21.3) 1.80 (1.30–2.20) 5.00 (4.30–5.90) 13.6 (11.4–16.8) 54.4 (33.2–86.5) 178 (134–324) 567 (238–1,350) 1,229
13.6 (10.8–17.1) 1.82 (1.55–2.16) 3.81 (3.33–4.87) 10.2 (8.36–12.9) 40.0 (24.9–62.5) 169 (93.3–316) 378 (229–685) 1,228
Race/ethnicity
Non-Hispanic white 27.7 (20.3–37.8) 2.30 (1.50–3.00) 6.80 (5.10–8.60) 23.5 (16.8–32.0) 120 (83.6–162) 501 (316–769) 1,250 (733–2,070) 1,092
28.3 (20.6–38.8) 2.55 (1.80–3.62) 6.07 (4.88–8.33) 21.9 (14.6–32.7) 116 (73.5–175) 510 (380–760) 1,330 (852–2,410) 1,091
Mexican American 16.5 (10.9–25.1) 2.30 (1.70–3.70) 5.00 (3.70–6.60) 11.9 (8.30–18.3) 45.5 (25.9–78.2) 176 (68.7–346) 412 (178–2,180) 613
15.1 (9.44–24.0) 2.39 (1.68–3.26) 4.10 (2.95–6.71) 11.0 (6.95–16.0) 40.7 (18.3–85.8) 158 (87.4–362) 595 (118–1,860) 612
Non-Hispanic black 12.8 (9.38–17.4) 2.10 (1.30–2.70) 4.60 (3.20–6.20) 10.2 (7.40–14.3) 34.2 (22.8–50.6) 127 (90.8–176) 209 (143–499) 652
8.78 (6.49–11.9) 1.50 (1.05–2.35) 3.18 (2.42–4.14) 6.80 (5.27–9.00) 19.6 (13.5–33.4) 78.1 (46.8–139) 185 (79.8–536) 651
aConcentrations are given as micrograms per liter (unshaded) and micrograms per gram creatinine (shaded), with 95% CIs in parentheses. bParticipants not defined by the three
racial/ethnic groups shown were included only in the total population estimate.(Bradley and Srivastava 1979). Additionally,
to further evaluate the relation between the
log-transformed BP-3 concentration and age,
we used age group (20–29, 30–39, 40–49,
and ≥ 50 years of age) as a categorical variable
in the model and generated a bar chart of
LSGM concentrations by age group.
To reach the final reduced model, we
used backward elimination with a threshold
of p < 0.05 for retaining the variable in the
model, using Satterwaite-adjusted F statistics.
We evaluated for potential confounding by
adding each of the excluded variables back
into the ﬁnal model one by one and examin-
ing changes in the β coefﬁcients of the statis-
tically signiﬁcant main effects or interactions.
If addition of one of these excluded variables
caused a change in a β coefﬁcient by ≥ 10%,
we re-added the variable to the model.
We also conducted weighted univariate
and multiple logistic regressions to examine the
association of BP-3 concentrations above the
95th percentile with sex, age group, and race/
ethnicity for all ages.
Results
We detected BP-3 in 96.8% of the 2,517
samples at concentrations ranging from 0.4 to
21,700 µg/L; the geometric mean and 95th
percentile concentrations were 22.9 µg/L
(22.2 µg/g creatinine) and 1,040 µg/L (1,070
µg/g creatinine), respectively (Table 1).
The final model for adults included sex,
race/ethnicity, age, age squared (p = 0.038),
creatinine concentration (log scale), and the
interaction terms creatinine*sex (p < 0.001)
and age*race/ethnicity (p = 0.04) (Table 2).
Females had signiﬁcantly higher BP-3 concen-
trations (p ≤ 0.04) than did males, regardless
of creatinine level [see Supplemental Tables S1
and S2 (http://www.ehponline.org/members/
2008/11269/suppl.pdf). Although BP-3 con-
centrations increased linearly as log creatinine
increased for both sexes (p < 0.001), the
increase was more pronounced for males than
for females (β for males, 1.12; for females,
0.65). Also, as age increased, BP-3 LSGM
concentrations showed a signiﬁcant quadratic
trend for Mexican Americans (p = 0.016) and
a significant linear positive trend for non-
Hispanic blacks (p = 0.022) but no signiﬁcant
linear or quadratic trend for non-Hispanic
whites (Figure 1). LSGM concentrations of
BP-3 for non-Hispanic whites were signifi-
cantly higher than for non-Hispanic blacks,
regardless of age (p ≤ 0.01), and signiﬁcantly
higher than for Mexican Americans only for
20- to 29-year-olds (p = 0.01). LSGM concen-
trations of BP-3 were signiﬁcantly higher for
Mexican Americans than for non-Hispanic
blacks only for 30- to 39-year-olds (p = 0.01)
[see Supplemental Tables S1 and S2 (http://
www.ehponline.org/members/2008/11269/
suppl.pdf)].
The ﬁnal model for children and adoles-
cents included sex (p < 0.001), race/ethnicity,
age, creatinine concentration (log scale)
(p < 0.001), and a race/ethnicity*age (p =
0.01) interaction term (Table 2). LSGM con-
centrations of BP-3 increased as log creatinine
increased (β = 0.77, p < 0.001). LSGM BP-3
concentrations for girls [30.2 µg/L; 95% con-
fidence interval (CI), 21.4–42.6 µg/L] were
signiﬁcantly higher (p < 0.001) than for boys
(16.1 µg/L; 95% CI, 13.2–19.8 µg/L). BP-3
concentrations also decreased linearly as age
increased (p = 0.0005) for non-Hispanic
whites but not for Mexican Americans and
non-Hispanic blacks [Figure 1; see also
Supplemental Table S3 (http://www.
ehponline.org/members/2008/11269/
suppl.pdf)]. LSGM concentrations of BP-3
for non-Hispanic whites were significantly
higher than LSGM concentrations for non-
Hispanic blacks, regardless of age, and for
Mexican Americans only at younger ages
[p < 0.001 at 8.5 years, p < 0.01 at 12 years;
Supplemental Table S4 (http://www.
ehponline.org/members/2008/11269/
suppl.pdf)]. LSGM BP-3 concentrations were
significantly higher for Mexican Americans
than for non-Hispanic blacks only for older
children (p = 0.01, at 12 and at 15.6 years,
p = 0.03 at 17.4 years) [Supplemental Table
S4 (http://www.ehponline.org/members/
2008/11269/suppl.pdf)].
For participants with urinary concentra-
tions above the 95th percentile of BP-3, sex
(p < 0.001) and race/ethnicity (p = 0.03), but
not age, were signiﬁcantly associated univari-
ately. In the final multiple logistics regres-
sion, sex (p < 0.001) and race/ethnicity (p =
0.03) were significant [Supplemental Table
S5 (http://www.ehponline.org/members/
2008/11269/suppl.pdf)]. Females were 3.5
times more likely than males to be above the
95th percentile [adjusted odds ratio (OR) =
3.5; 95% CI, 1.9–6.5]. Non-Hispanic whites
were 6.8 times more likely to have BP-3 con-
centrations above the 95th percentile
(adjusted OR = 6.8; 95% CI, 2.9–16.2) than
were non-Hispanic blacks, and Mexican
Americans were four times more likely to be
above the 95th percentile (adjusted OR =
4.04; 95% CI, 1.1–15.5) than were non-
Hispanic blacks. We found no signiﬁcant dif-
ference between non-Hispanic whites and
Mexican Americans.
Exposure assessment of the U.S. population to benzophenone-3
Environmental Health Perspectives • VOLUME 116 | NUMBER 7 | July 2008 895
Table 2. Coefﬁcients for the signiﬁcant variables from the multiple regression models of the BP-3 urinary
concentration (log-transformed) by age group [β coefﬁcient (p-value)].
Children and adolescents Adults
Variable (6–19 years of age) (≥ 20 years of age)
Intercept  –0.33985 (0.14913)  –0.08999 (0.73675)
Sex
Male  –0.27143 (0.00079)  –1.39213 (0.00079)
Female Reference
Race/ethnicity
Mexican American  0.01857 (0.91283)  0.24104 (0.15686)
Non-Hispanic white 0.73888 (0.00035) 0.48352 (0.00001)
Non-Hispanic black Reference
Age –0.00243 (0.73485) 0.00155 (0.50696)a
Creatinine concentration (log transformed)  0.76653 (<0.001) 0.64519 (0.00008)
Age squared (centered) –0.00018 (0.03848)
Race/ethnicity*age
Mexican American 0.01139 (0.4116) –0.00365 (0.2125)a
Non-Hispanic white –0.02787 (0.0249) –0.00784 (0.02026)a
Non-Hispanic black Reference
Sex*log creatinine
Male 0.47423 (0.00811)
Female Reference
aAge centered at 50 years.
Figure 1. LSGM concentrations of BP-3 (in micrograms per liter) by age and race/ethnicity: (A) children
and adolescents and (B) adults. Error bars indicate 95% CIs.
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The detection of BP-3 in almost all samples
suggests that exposure to BP-3 was widespread
in the U.S. general population during
2003–2004. This high level of detection most
likely resulted from routine use of consumer
products that contain BP-3, such as sunscreen,
skin care lotion, lipstick, and hair spray
(National Library of Medicine 2007). The
wide range of urinary concentrations—10%
of participants had BP-3 concentrations
< 2.3 µg/g creatinine and 5% had concentra-
tions > 1,070 µg/g creatinine (Table 1)—may
be related to lifestyle differences that result in
exposure differences and to individual varia-
tions in bioavailability, distribution kinetics,
or metabolism of BP-3.
The frequent detection of BP-3 and the
magnitude and range of urinary concentra-
tions in NHANES 2003–2004 are compara-
ble with data from two smaller studies in the
United States. In 30 anonymous adult volun-
teers with no documented BP-3 exposure, we
detected BP-3 in 90% of samples, and total
urinary concentration (free plus conjugates)
of BP-3 ranged from the LOD (0.5 µg/L) to
3,000 µg/L (Ye et al. 2005b). In a pilot study
of 90 prepubertal girls from New York City,
New York; Cincinnati, Ohio; and Northern
California, we detected BP-3 in 86% of sam-
ples (Wolff et al. 2007). The creatinine-
adjusted geometric mean concentration of
BP-3 (30.8 µg/g) for these girls was similar to
that for NHANES 2003–2004 children 6–11
years of age (25.8 µg/g creatinine).
The relation between age and LSGM BP-3
concentrations differed by race/ethnicity
(Figure 1). These differences most likely result
from increased use of sunscreen or other per-
sonal-care products containing BP-3 by people
with light skin pigmentation. For instance,
sunscreen use among non-Hispanic whites is
reportedly higher than for non-Hispanic blacks
and other race/ethnic groups of outdoor work-
ers and the general population (Briley et al.
2007; Pichon et al. 2005). Likewise, differ-
ences by age might reﬂect differences in use of
personal-care products that contain BP-3.
Non-Hispanic white parents may apply sun-
screen regularly to protect their young children
from sunburn, whereas teenagers might not
apply sunscreen as often (Jones and Saraiya
2006; Livingston et al. 2007). Non-Hispanic
white adults in their twenties and forties might
be more preoccupied about their skin appear-
ance than non-Hispanic whites in their thirties
(who may devote more time to work and fam-
ily responsibilities than to themselves) or peo-
ple in their ﬁfties (who may see little beneﬁt in
applying sunscreen at older ages).
We found differences by sex in the
adjusted LSGM concentrations of BP-3.
Compared with males, females tend to use
more sunscreen (Eide and Weinstock 2006;
Hall et al. 1997; Jones and Saraiya 2006) and
other personal-care products that may contain
BP-3. Therefore, higher concentrations of
BP-3 for females than for males most likely
result from their higher exposure to BP-3.
Females and non-Hispanic whites not
only had signiﬁcantly higher LSGM concen-
trations than did males and non-Hispanic
blacks, respectively, but also were more likely
to exhibit concentrations of BP-3 above the
95th percentile. In particular, females were 3.5
times more likely than males, and non-
Hispanic whites were 6.8 times more likely
than non-Hispanic blacks to have BP-3 con-
centrations above the 95th percentile.
Mexican Americans were about four times
more likely than non-Hispanic blacks to pre-
sent BP-3 concentrations above the 95th per-
centile. Although young children had LSGM
concentrations of BP-3 comparable with those
of adults in their twenties and forties, age was
not significantly associated with having con-
centrations above the 95th percentile. Our
data suggest that females and non-Hispanic
whites represent two segments of the general
population with higher exposures to BP-3
compared with other demographic groups.
Protection against sunburn and squamous
cell carcinoma by application of sunscreens is
important, even though the use of sunscreen
may not protect against melanoma, the dead-
liest form of skin cancer (Lin and Fisher 2007).
Sun protection is critical for outdoor workers,
who are at higher risk for squamous cell carci-
noma than other population groups (Pichon
et al. 2005), and in situations where sun expo-
sure, even during peak times, is unavoidable. In
other situations, although behavioral measures,
such as wearing a hat, sunglasses, and sun pro-
tective clothes and avoiding the sun during
peak exposure times, can reduce the risk for
skin damage, sunscreens may be the primary
means of sun protection, especially in societies
that value outdoor activities (Lautenschlager
et al. 2007). Toxicologic and epidemiologic
data on BP-3, one of these sunscreens, are lack-
ing. Nevertheless, the NHANES 2003–2004
data demonstrating Americans’ exposure to
BP-3 can be used to establish a nationally repre-
sentative baseline assessment of exposure to this
sunscreen agent and may promote the use of
biomonitoring to complement the question-
naire or survey information in studies designed
to evaluate sun-safety practices. These
NHANES 2003–2004 data could also be of
beneﬁt in a risk assessment for BP-3 if indicated
by toxicologic or epidemiologic studies.
REFERENCES
Balmer ME, Buser HR, Muller MD, Poiger T. 2005. Occurrence of
some organic UV ﬁlters in wastewater, in surface waters,
and in ﬁsh from Swiss lakes. Environ Sci Technol 39:953–962.
Bradley RA, Srivastava SS. 1979. Correlation in polynomial
regression. Am Stat 33:11–14.
Briley JJ, Lynfield YL, Chavda K. 2007. Sunscreen use and
usefulness in African-Americans. J Drugs Dermatol
6:19–22.
CDC. 2003. National Health and Nutrition Examination Survey.
National Center for Health Statistics. Atlanta, GA:Centers for
Disease Control and Prevention. Available: http://www.
cdc.gov/nchs/about/major/nhanes/intro_mec.htm [accessed
11 May 2007].
CDC. 2006a. Analytic and Reporting Guidelines. The National
Health and Nutrition Examination Survey (NHANES). Atlanta,
GA:Centers for Disease Control and Prevention. Available:
http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/
nhanes_analytic_guidelines_dec_2005.pdf [accessed
12 March 2007].
CDC. 2006b. General Documentation on Laboratory Data.
General Information about the NHANES 2003–2004
Laboratory Methodology and Public Data Files. Atlanta,
GA:Centers for Disease Control and Prevention. Available:
http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/lab_
c_generaldoc.pdf [accessed 30 July 2007].
Cuderman P, Heath E. 2007. Determination of UV filters and
antimicrobial agents in environmental water samples.
Anal Bioanal Chem 387:1343–1350.
Daughton CG. 2002. Environmental stewardship and drugs as
pollutants. Lancet 360:1035–1036.
Daughton CG, Ternes TA. 1999. Pharmaceuticals and personal
care products in the environment: agents of subtle
change? Environ Health Perspect 107:907–938.
Eide MJ, Weinstock MA. 2006. Public health challenges in sun
protection. Dermatol Clin 24:119–124.
Felix T, Hall BJ, Brodbelt JS. 1998. Determination of benzophe-
none-3 and metabolites in water and human urine by
solid-phase microextraction and quadrupole ion trap GC-
MS. Anal Chim Acta 371:195–203.
Gonzalez H, Farbrot A, Larko O, Wennberg AM. 2006.
Percutaneous absorption of the sunscreen benzophe-
none-3 after repeated whole-body applications, with and
without ultraviolet irradiation. Br J Dermatol 154:337–340.
Hall HI, May DS, Lew RA, Koh HK, Nadel M. 1997. Sun protec-
tion behaviors of the US white population. Prev Med
26:401–407.
Hayden CGJ, Cross SE, Anderson C, Saunders NA, Roberts MS.
2005. Sunscreen penetration of human skin and related
keratinocyte toxicity after topical application. Skin
Pharmacol Physiol 18:170–174.
Hornung RW, Reed LD. 1990. Estimation of average concentra-
tion in the presence of nondetectable values. Appl Occup
Environ Hyg 5:46–51.
Janjua NR, Mogensen B, Andersson AM, Petersen JH,
Henriksen M, Skakkebæk NE, et al. 2004. Systemic absorp-
tion of the sunscreens benzophenone-3, octyl-methoxy-
cinnamate, and 3-(4-methyl-benzylidene) camphor after
whole-body topical application and reproductive hormone
levels in humans. J Invest Dermatol 123:57–61.
Jiang R, Roberts MS, Collins DM, Benson HAE. 1999.
Absorption of sunscreens across human skin: an evalua-
tion of commercial products for children and adults. Br J
Clin Pharmacol 48:635–637.
Jones SE, Saraiya M. 2006. Sunscreen use among US high
school students, 1999–2003. J Sch Health 76:150–153.
Kadry AM, Okereke CS, Abdelrahman MS, Friedman MA, Davis
RA. 1995. Pharmacokinetics of benzophenone-3 after oral-
exposure in male-rats. J Appl Toxicol 15:97–102.
Lautenschlager S, Wulf HC, Pittelkow MR. 2007. Photo-
protection. Lancet 370:528–537.
Lin JY, Fisher DE. 2007. Melanocyte biology and skin pigmenta-
tion. Nature 445:843–850.
Livingston PM, White V, Hayman J, Dobbinson S. 2007.
Australian adolescents’ sun protection behavior: who are
we kidding? Prev Med 44:508–512.
Loraine GA, Pettigrove ME. 2006. Seasonal variations in con-
centrations of pharmaceuticals and personal care prod-
ucts in drinking water and reclaimed wastewater in
southern California. Environ Sci Technol 40:687–695.
Ma RS, Cotton B, Lichtensteiger W, Schlumpf M. 2003. UV fil-
ters with antagonistic action at androgen receptors in the
MDA-kb2 cell transcriptional-activation assay. Toxicol Sci
74:43–50.
Morohoshi K, Yamamoto H, Kamata R, Shiraishi F, Koda T,
Morita M. 2005. Estrogenic activity of 37 components of
commercial sunscreen lotions evaluated by in vitro
assays. Toxicol In Vitro 19:457–469.
National Library of Medicine. 2007. Household Products
Calafat et al.
896 VOLUME 116 | NUMBER 7 | July 2008 • Environmental Health PerspectivesDatabase. Bethesda, MD:National Institutes of Health.
Available: http://hpd.nlm.nih.gov/index.htm [accessed
4 June 2007].
National Toxicology Program. 1992. NTP Technical Report on
Toxicity Studies of 2-Hydroxy-4-methoxybenzophenone
(CAS Number: 131-57-7) Administered Topically and in
Dosed Feed to F344/N Rats and B6C3F1 Mice. Research
Triangle Park, NC:National Toxicology Program, National
Institute of Environmental Health Sciences, U.S.
Department of Health and Human Services.
Okereke CS, Abdelrahman MS, Friedman MA. 1994. Disposition
of benzophenone-3 after dermal administration in male
rats. Toxicol Lett 73:113–122.
Okereke CS, Barat SA, Abdelrahman MS. 1995. Safety
Evaluation of benzophenone-3 after dermal administration
in rats. Toxicol Lett 80:61–67.
Okereke CS, Kadry AM, Abdelrahman MS, Davis RA, Friedman
MA. 1993. Metabolism of benzophenone-3 in rats. Drug
Metab Dispos 21:788–791.
Pichon LC, Mayer JA, Slymen DJ, Elder JP, Lewis EC, Galindo
GR. 2005. Ethnoracial differences among outdoor workers
in key sun-safety behaviors. Am J Prev Med 28:374–378.
Rastogi SC. 2002. UV filters in sunscreen products—a survey.
Contact Derm 46:348–351.
Sarveiya V, Risk S, Benson HAE. 2004. Liquid chromatographic
assay for common sunscreen agents: application to
in vivo assessment of skin penetration and systemic
absorption in human volunteers. J Chromatogr B Anal
Technol Biomed Life Sci 803:225–231.
Schlumpf M, Cotton B, Conscience M, Haller V, Steinmann B,
Lichtensteiger W. 2001. In vitro and in vivo estrogenicity of
UV screens. Environ Health Perspect 109:239–244.
Schlumpf M, Durrer S, Maerkel K, Ma R, Conscience M,
Fleischmann I, et al. 2003. Endocrine activity and develop-
mental toxicity of UV ﬁlters. Toxicol Sci 72:649.
Schlumpf M, Jarry H, Wuttke W, Ma R. 2004a. Estrogenic activ-
ity and estrogen receptor beta binding of the UV filter
3-benzylidene camphor comparison with 4-methylbenzyli-
dene camphor. Toxicology 199:109–120.
Schlumpf M, Schmid P, Durrer S, Conscience M, Maerkel K,
Henseler M, et al. 2004b. Endocrine activity and develop-
mental toxicity of cosmetic UV filters—an update.
Toxicology 205:113–122.
Schreurs RHMM, Sonneveld E, Jansen JHJ, Seinen W, van der
Burg B. 2005. Interaction of polycyclic musks and UV fil-
ters with the estrogen receptor (ER), androgen receptor
(AR), and progesterone receptor (PR) in reporter gene
bioassays. Toxicol Sci 83:264–272.
Stackelberg PE, Furlong ET, Meyer MT, Zaugg SD, Henderson
AK, Reissman DB. 2004. Persistence of pharmaceutical
compounds and other organic wastewater contaminants
in a conventional drinking-water treatment plant. Sci Total
Environ 329:99–113.
Suzuki T, Kitamura S, Khota R, Sugihara K, Fujimoto N, Ohta S.
2005. Estrogenic and antiandrogenic activities of 17 ben-
zophenone derivatives used as UV stabilizers and sun-
screens. Toxicol Appl Pharmacol 203:9–17.
Taylor JK. 1987. Quality Assurance of Chemical Measurements.
Chelsea, MI:Lewis Publishers.
Wolff MS, Teitelbaum SL, Windham G, Pinney SM, Britton JA,
Chelimo C, et al. 2007. Pilot study of urinary biomarkers of
phytoestrogens, phthalates, and phenols in girls. Environ
Health Perspect 115:116–121.
Ye XY, Kuklenyik Z, Needham LL, Calafat AM. 2005a. Automated
on-line column-switching HPLC-MS/MS method with peak
focusing for the determination of nine environmental phe-
nols in urine. Anal Chem 77:5407–5413.
Ye XY, Kuklenyik Z, Needham LL, Calafat AM. 2005b.
Quantification of urinary conjugates of bisphenol A, 2,5-
dichlorophenol, and 2-hydroxy-4-methoxybenzophenone
in humans by online solid phase extraction-high perfor-
mance liquid chromatography-tandem mass spectrometry.
Anal Bioanal Chem 383:638–644.
Exposure assessment of the U.S. population to benzophenone-3
Environmental Health Perspectives • VOLUME 116 | NUMBER 7 | July 2008 897